The firm said it can detect circulating tumor DNA with a mutational allele frequency of 0.001 percent, enabled by digital PCR and the firm's proprietary chemistry.
The firm is validating two biomarkers that it hopes will stratify patients for its investigational drug for pediatric minimally verbal autism.
The firm is in the midst of a clinical trial called NOVA to compare its circulating-tumor DNA-based Colvera test to DiaSorin's carcinoembryonic antigen assay.
Researchers used Mission Bio's Tapestri assay to identify and monitor the evolution of cancer mutations in acute myeloid leukemia in response to targeted treatment.
The University of Michigan researchers aim to commercialize the Hydro-Seq microfluidic platform, which isolates and prepares single circulating tumor cells for RNA sequencing.
The firm launched a study this year to validate the new CRC-specific immune-transcriptomic assay, aiming to obtain regulatory approval in Europe.
The method's developers believe that clinicians could use approach to predict how high-grade, serous ovarian cancer patients will respond to chemotherapy.
Kiyatec's cell-based assays model and predict patient therapeutic response to drive cancer drug development and potentially guide treatment.
The firm's "TuMatch" assay integrates patient whole-exome sequencing data and fruit fly models to develop a personalized drug therapy service for cancer patients.
New US Department of Commerce rules will affect supercomputing in China, according to the Wall Street Journal.
A new analysis finds that it will be more than a century until female computer scientists publish at the same rate as their male counterparts, ScienceInsider reports.
Broad Institute researchers describe an approach they've dubbed "DNA microscopy."
In PLOS this week: epigenetic changes following hepatitis C virus treatment, metagenomic analysis of Ugandan children with febrile illness, and more.